Financials
Financial year 2025
Apotheek Vijve from Waregem, company number BE0439305377, closed financial year 2025 with a result of € 83,539 after tax. For that financial year Apotheek Vijve recorded a gross margin of € 244,417 and equity of € 746,973. Compared with financial year 2024, the result moved from € 104,630 to € 83,539. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 746,973
▲ 6% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 83,539
▼ 20% vs 2024
Profit after tax over the fiscal year.
€ 246,303
▲ 14% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 40,000 paid out
48 % of the profit went to the shareholders, mostly to Garju Pharma (100 % of the shares). That is where the money ends up.
People and assets in 2025
1.7
▲ 0.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 118,593
▲ 44% vs 2024
€ 69,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 14,772
▼ 20% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 76,113
▼ 17% vs 2024
€ 10,501 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 86,709
▲ 4% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 14,410
▼ 17% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 174,963 | € 258,981 | € 232,924 | € 244,417 | ▲ 5% |
| Profit after taxes | € 45,899 | € 102,781 | € 104,630 | € 83,539 | ▼ 20% |
| Equity | € 616,023 | € 638,803 | € 703,434 | € 746,973 | ▲ 6% |
| Total debts | € 234,308 | € 291,628 | € 232,534 | € 217,154 | ▼ 7% |
| Cash | € 299,583 | € 143,910 | € 215,576 | € 246,303 | ▲ 14% |
| Land & buildings | - | € 15,090 | € 13,435 | € 11,780 | ▼ 12% |
| Retained profit | € 546,023 | € 568,803 | € 633,434 | € 676,973 | ▲ 7% |
| Dividend | € 10,000 | € 80,000 | € 40,000 | € 40,000 | |
| Bank debt | € 105,852 | € 96,225 | € 91,769 | € 76,113 | ▼ 17% |
| Balance sheet total | € 850,331 | € 930,431 | € 935,968 | € 964,127 | ▲ 3% |
| Employees (FTE) | 1.9 | 1.8 | 1.2 | 1.7 | ▲ 0.5 |
Key figures of Apotheek Vijve, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Apotheek Vijve?
What happened at Apotheek Vijve in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 83,539 (▼ 20% vs 2024). Source: NBB ↗
- Garju Pharma B.V. became a director. NBB
- New establishment in Waregem. KBO
- Start of the company according to the CBE. KBO
In short
From € 45,899 profit in 2022 to € 83,539 profit in 2025.
Paid € 47,970 in corporate taxes since 2022.
Best year ever: 2024, with € 104,630 profit.
On average € 143,800 of value added per employee in 2025.
A new publication or filing at Apotheek Vijve? We notify you, reason included.
Follow Apotheek VijveDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Garju Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Apotheek VijveBehind Apotheek Vijve is Garju Pharma B.V.. The shares are held by Garju Pharma (100%). It owns Febelco itself.
Directors
According to the 2025 annual accounts
bestuurder · represented by Stéphanie Goeminne
since 2022
Shareholders
100%
Participations
Establishments
Establishment units
Physical locations of this company
Aloise Biebuyckstraat 13
8793 Waregem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
UPCLOUD, FI
Website info
Features
Security
Network
Details
- Company number
- 0439.305.377
- VAT number
- BE 0439.305.377
- Registered office
- Aloise Biebuyckstraat 13, 8793 Waregem
- Names & denominations
- Apotheek Vijve
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 11 December 1989
- Peppol
- Active · Active since 24 Nov 2023
- Contact
- apotheekvijve.be
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers